Natural Course of Severe Oligozoospermia in Infertile Male: Influence on Future Fertility Potential

Koo²,

et al. 2017

World J Mens Health

PurposeWe investigated the protective effect of a mixture of 2 herbal extracts, KH-465, which consisted of Epimedium koreanum Nakai and Angelica gigas Nakai, on spermatogenesis in a luteinizing hormone-releasing hormone (LHRH) agonist-induced rat model of male infertility.Materials and MethodsSeventy-five 12-week-old male Sprague-Dawley rats were randomly divided into 5 groups, containing 15 rats each: a normal control group that received no treatment and 4 experimental groups (I, II, III, and IV) in which an LHRH agonist was administered for 4 weeks to induce spermatogenic failure. Group I received distilled water, and groups II, III, and IV received 200 mg/kg/day of KH-465, 400 mg/kg/day KH-465, and depo-testosterone for 4 weeks, respectively. Weight changes of the testis and epididymis, sperm count motility, and levels of testosterone (T), free T, follicle-stimulating hormone (FSH), luteinizing hormone (LH), superoxide dismutase (SOD), and 8-hydroxy-2′-deoxyguanosine (8-OHdG) were estimated.ResultsBody, testis, and epididymis weight showed no significant differences among the control and experimental groups. Treatment with KH-465 increased the sperm count and motility. Serum hormone levels of T, free T, and FSH were not significantly different in the experimental groups, while the LH level was higher than in the LHRH agonist-induced control group, but not to a significant extent. Levels of SOD were higher and 8-OHdG were lower in the groups that received KH-465 than in the LHRH agonist-induced control group.ConclusionsOur results suggest that KH-465 increased sperm production via reducing oxidative stress and had a positive effect in a male infertility model.

Section: Introductionmentioning

confidence: 99%

Restoration of Spermatogenesis Using a New Combined Herbal Formula of Epimedium koreanum Nakai and Angelica gigas Nakai in an Luteinizing Hormone-Releasing Hormone Agonist-Induced Rat Model of Male Infertility

Koo²,

et al. 2017

World J Mens Health

Fertility and Sterility

“…In addition, sperm cryopreservation is increasingly used in case of other disorders, such as autoimmune diseases and myelodysplastic syndromes requiring treatments that may affect reproductive functions. Moreover, sperm cryopreservation is offered to patients with severe oligospermia (or even cryptozoospermia) or ejaculatory disorders with the intent of using cryopreserved sperm in case no sperm are found in the ejaculates on the day of intracytoplasmic sperm injection (ICSI) (1) to have sperm available in the event of a decline in sperm count, which may occur in these patients (2). Cryopreservation of spermatozoa was introduced in the early 1960s and is performed with different procedures.…”

mentioning

confidence: 99%

Semen cryopreservation for men banking for oligospermia, cancers, and other pathologies: prediction of post-thaw outcome using basal semen quality

Degl'Innocenti

Filimberti

Magini

et al. 2013

Objective: To evaluate post-thawing sperm parameters in a large series of men cryopreserving for different cancers and oligospermia. Design: Retrospective observational study. Setting: Semen cryopreservation laboratory. Patient(s): Six hundred twenty-three patients undergoing semen cryopreservation for cancer or oligospermia who discontinued banking. Intervention(s): None. Main Outcome Measure(s): Postcryopreservation sperm motility and viability. Result(s): In oligospermic men, recovery of motile sperm after cryopreservation was possible in only a few out of the 219 samples cryopreserved for this problem. Similarly, independent of the reason for which cryopreservation was required, if one basal semen parameter fell below the 5th percentile of the World Health Organization reference values, recovery of motile and viable spermatozoa after thawing was low. Among samples cryopreserved for cancer, those with testicular cancer showed the lowest basal semen quality and recovery after thawing. In cases of hematological cancers or other types of cancers, motility recovery was similar to that of non-cancerrelated samples. Receiver operating characteristic analyses demonstrate that basal progressive and total motility predict the recovery rate of motile sperm after thawing with high accuracy, sensibility and specificity. Conclusion(s): Our study demonstrates the ability of prefreeze semen parameters to predict cryosurvival in terms of sensitivity and precision. Using this information, the clinician could perform appropriate counseling about the future possibilities of fertility for the patient. (Fertil Steril Ò 2013;100:1555-63.

“…The sperm concentration has the widest intra‐individual variance, while sperm vitality is the most stable parameter (Alvarez et al ., ). Infertile men may experience a decrease in sperm count over time, even become azoospermic or show a decrease to a very severe level and have to undergo a TESE (Song et al ., ).…”

Section: Discussionmentioning

confidence: 97%

Treatment strategies for severe oligoasthenoteratozoospermia (OAT) (<0.1 million/mL) patients

et al. 2015

SUMMARYIntracytoplasmic sperm injection (ICSI) using spermatozoa from patients with severe oligoasthenoteratozoospermia is still a challenge. Although spermatozoa are available, lower fertilisation rates as well as compromised pregnancy rates are observed after ICSI. We aimed at identifying respective parameters in the pre-values of ejaculate samples used for couple counselling. The clinical prevalues of 121 patients and their corresponding 228 ICSI cycles performed between 2002 and 2010 were retrospectively analysed. Patients were divided into three groups: (i) group 1 (G1, n = 51) where all patients showed at least once <0.1 million/mL and ICSI was performed using ejaculate alone; (ii) group 2 (G2, n = 14) patients had once <0.1 Mill/mL or azoospermia and a testicular biopsy before start of ICSI; (iii) group 3 (G3, n = 56) patients were azoospermic and directed immediately to testicular sperm extraction (TESE). The pre-values of G2 differed significantly from G1 in terms of volume and motility. Lutenizing hormone (LH) and follicle-stimulating hormone (FSH) values were equal in G1 and G2, but showed significant differences in comparison to G3. Testis volume was significantly higher in G3. In the corresponding ICSI cycles, the percentage of cancelled embryo transfers was highest in G3. We did not find any correlations of hormonal markers or sperm pre-values with the success rates of ICSI. In our patient cohort, spermatozoa retrieved either from ejaculate or testicular biopsies have nearly identical chances in achieving pregnancies. Patients in need of TESE before ICSI have significantly lower sperm counts. However, it is not possible to calculate threshold values as indicator for TESE.